At ENA, Auron will present in vitro and in vivo data from AUTX-703 its oral, potent and selective degrader targeting KAT2A/B, a histone acetyltransferase that is associated with multiple tumor types, ...
Scientists have developed a novel peptide that could potentially revolutionize the treatment of Alzheimer's disease and other neurodegenerative disorders known as tauopathies.